RegeneRx, Digital Aria sign two product license agreements

RegeneRx Biopharmaceuticals and Digital Aria have entered into two product license agreements to develop RegeneRx’s RGN-259 preservative-free eye drop product candidate in Asia and its RGN-137 topical dermal gel product candidate in the U.S., according to a press release. License terms include commercial milestone payments of up to $7 million and a double-digit royalty on any commercial sales. Digital Aria has to initiate phase 2 clinical trials in the U.S. and Australia within 3 years, the release said.

Full Story →